CRISPR vs Enzymes in Viral Metagenomics: Why the Classic Method Still Wins

Researchers have successfully mapped complete genomes of elusive zoonotic pathogens from degraded tissue, but achieving this required overcoming a massive signal-to-noise problem. The primary challenge in viral metagenomics is that host and bacterial genetic material heavily obscures the actual virus. To address this, scientists directly compared a highly targeted CRISPR-Cas9 method against a standard enzymatic approach to determine which clears the background noise best.

The Signal-to-Noise Problem in Viral Metagenomics

When scientists search for unknown pathogens, they sequence all the genetic material in a given sample. This approach works in theory, but in practice, ribosomal RNA (rRNA) from the host animal or local bacteria fills up most of the sequencing data. This wasted sequencing space drives up costs and severely lowers diagnostic sensitivity. For years, laboratories have relied on RNase H-based enzymes, such as Illumina's Ribo-Zero Plus, to digest this unwanted rRNA. Recently, CRISPR-Cas9 emerged as an alternative, using guide RNAs to snip away the genetic clutter. The theory suggests that CRISPR could offer superior precision, but empirical data on its performance across diverse animal tissues remained scarce until now.

Putting CRISPR and Enzymes to the Test

The research team measured the performance of both methods using 12 difficult samples of varying RNA integrity. They targeted the following pathogens across different host species:

• Rabies lyssavirus
• Influenza A virus
• West Nile virus
• Norovirus

The samples ranged from pristine, high-quality RNA to highly degraded genetic material. The data showed that the CRISPR-Cas9 system, specifically Jumpcode CRISPRclean Plus, efficiently reduced rRNA content to 14.5 percent. Despite this targeted reduction, the older enzymatic method drastically outperformed the newer technology in recovering the actual viral reads. The Ribo-Zero enzymatic approach achieved up to a 60.7-fold enrichment of the target viruses. Both techniques successfully produced complete viral consensus genomes, but only when the initial viral load and RNA quality were already sufficient.

Why the Old Method Still Leads

Based on these measurements, enzymatic depletion is currently more efficient and cost-effective for everyday laboratory use. The data suggests that laboratories will likely stick with established RNase H-based methods for routine diagnostic work. However, this study does not solve the fundamental issue of low-titre viral detection in highly degraded samples. If a tissue sample has very little virus and poor RNA quality, neither the CRISPR nor the enzymatic method can reliably reconstruct the full pathogen genome. The background host material still overwhelms the scarce viral fragments. The CRISPR workflow requires further optimisation before it can compete with established protocols in a clinical or field setting. While CRISPR technology is undeniably brilliant for precise gene editing, the current findings indicate it may not yet be the optimal tool for broad viral surveillance.